Subject(s)
Anti-Infective Agents/adverse effects , Anticoagulants/adverse effects , Gastrointestinal Hemorrhage/chemically induced , Nalidixic Acid/adverse effects , Postoperative Hemorrhage/chemically induced , Warfarin/adverse effects , Aged , Anti-Infective Agents/therapeutic use , Anticoagulants/therapeutic use , Drug Interactions , Gastrointestinal Hemorrhage/diagnosis , Humans , Ischemia/surgery , Leg/blood supply , Leg/surgery , Male , Nalidixic Acid/therapeutic use , Postoperative Hemorrhage/diagnosis , Thromboembolism/prevention & control , Urethritis/complications , Urethritis/drug therapy , Warfarin/therapeutic useSubject(s)
Hypertension/epidemiology , Occupational Medicine , Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , RiskABSTRACT
The intravenous form of the Soviet anti-arrhythmic pharmaceutical ethacizine has been studied clinically. The pharmaceutical was administered to 30 patients with ventricular rhythm disorders during 3 to 15 minutes, at an average dose of 0.63 mg per 1 kg body weight, under the Holter monitor control. On the average the effect became apparent 6.5 min, after the injection and lasted on the average 149 +/- 15 min. Etacizine was effective in 77% of cases. It was established that there was no pronounced negative effect on the heart rate and the arterial pressure. Uzineg the tetrapolar rheography method it was shown that there was no pronounced negative effect on the central hemodynamics. The observation was made that etacizine induced a moderate decrease of the conductivity in atria AV-system and ventricles. Etacisin could be successfully used for rapid suppression of the ventricle rhythm disorders in various forms of coronary disease of the heart.
Subject(s)
Anti-Arrhythmia Agents/therapeutic use , Cardiac Complexes, Premature/drug therapy , Moricizine/analogs & derivatives , Phenothiazines/therapeutic use , Tachycardia, Paroxysmal/drug therapy , Adult , Aged , Cardiac Complexes, Premature/physiopathology , Female , Heart Ventricles/physiopathology , Hemodynamics/drug effects , Humans , Male , Middle Aged , Tachycardia, Paroxysmal/physiopathologySubject(s)
Adipose Tissue/enzymology , Coronary Disease/diet therapy , Diet, Reducing , Phospholipases A/metabolism , Phospholipases/metabolism , Adult , Coronary Disease/complications , Coronary Disease/enzymology , Humans , Lipids/blood , Lipoproteins/blood , Male , Middle Aged , Obesity/complications , Phospholipases A/bloodSubject(s)
Dopamine/therapeutic use , Glucagon/therapeutic use , Heart Failure/drug therapy , Isoproterenol/therapeutic use , Adult , Aged , Blood Pressure , Cardiac Output , Female , Heart Rate , Humans , Male , Middle Aged , Myocardial Contraction , Stroke VolumeSubject(s)
Hemodynamics/drug effects , Nitroglycerin/therapeutic use , Adult , Aged , Angina Pectoris/drug therapy , Angina Pectoris/physiopathology , Female , Humans , Male , Middle AgedABSTRACT
It has been shown with special reference to 35 patients suffering from myocardial infarction, atherosclerotic cardiosclerosis and rheumatic heart diseases associated with varying degrees of circulatory insufficiency that the final amount of distribution and halflife of lidocaine directly correlated with the cardiac index. A formula has been suggested for calculating the amount of distribution of the drug on the basis of the cardiac index. It has been demonstrated that the formula can be used for the development of therapeutically effective lidocaine concentration in the patients' blood.
Subject(s)
Heart Failure/blood , Lidocaine/blood , Coronary Disease/blood , Coronary Disease/drug therapy , Heart Failure/drug therapy , Humans , Kinetics , Lidocaine/administration & dosage , Mathematics , Myocardial Infarction/blood , Myocardial Infarction/drug therapy , Rheumatic Heart Disease/blood , Rheumatic Heart Disease/drug therapy , Time FactorsABSTRACT
The pharmacodynamics and pharmacotherapy of phosphaden (adenosine-5-monophosphate), a Soviet activator of energy metabolism, were studied in patients with chronic ischemic heart disease. Functional and biochemical methods were used. It was established that phosphaden is an effective drug in the treatment of chronic ischemic heart disease. The results of clinical, functional and biochemical examination support this conclusion.